Watch CVS. Know when insiders buy.
One email the day a filing lands. Free.
Work order
78
PASS · shorts 78
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
4 / 15
tracked funds hold it
Calls on record
0
nobody we score has called it yet
MKT CAP $123.7BP/E 25.5DIV YIELD 2.75%FCF YIELD 9.50%REV TTM $415.1B +7.4%NET INCOME $4.9B +7.9%NET DEBT $57.7B52W 70.08 – 110.60SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $106.1B | +7.3% | 44.5% | $4.7B | $3B | +191.8% | 2.31 | $6.3B | $691M | $5.7B | Aug 5 |
| Q1 2026 · Mar 31 | $100.4B | +6.2% | 44.8% | $4.7B | $2.9B | +65.4% | 2.30 | $4.2B | $849M | $3.4B | Aug 5 |
| Q4 2025 · Dec 31 | $105.7B | +8.2% | 44.1% | $2.1B | $2.9B | +79.0% | 2.32 | $3.4B | $784M | $2.6B | Feb 10 |
| Q3 2025 · Sep 30 | $102.9B | +7.8% | 44.5% | −$3.2B | −$4B | −4669.0% | -3.13 | $796M | $698M | $98M | Feb 10 |
| Q2 2025 · Jun 30 | $98.9B | +8.4% | 45.4% | $2.4B | $1B | −42.3% | 0.80 | $1.9B | $607M | $1.3B | Aug 5 |
| Q1 2025 · Mar 31 | $94.6B | +7.0% | 46.0% | $3.4B | $1.8B | +59.8% | 1.41 | $4.6B | $743M | $3.8B | Aug 5 |
| Q4 2024 · Dec 31 | $97.7B | +4.2% | 43.4% | $2.4B | $1.6B | −19.6% | 1.31 | $1.9B | $768M | $1.1B | Feb 10 |
| Q3 2024 · Sep 30 | $95.4B | +6.3% | 44.5% | $832M | $87M | −96.2% | 0.07 | −$745M | $670M | −$1.4B | Feb 10 |
| Q2 2024 · Jun 30 | $91.2B | — | 45.2% | $3B | $1.8B | — | 1.41 | $3.1B | $638M | $2.5B | Feb 10 |
| Q1 2024 · Mar 31 | $88.4B | — | 45.6% | $2.3B | $1.1B | — | 0.88 | $4.9B | $705M | $4.2B | Feb 10 |
| Q4 2023 · Dec 31 | $93.8B | — | 38.8% | $3.4B | $2B | — | 1.59 | −$2.6B | $911M | −$3.5B | Feb 10 |
| Q3 2023 · Sep 30 | $89.8B | — | 39.1% | $3.7B | $2.3B | — | 1.75 | $2.7B | $545M | $2.2B | Feb 10 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $402.1B | 45.0% | $4.7B | $1.8B | 0.4% | 1.39 | $10.6B | $2.8B | $7.8B | $0 | $3.4B |
| FY2024 · to Dec 31 | $372.8B | 44.7% | $8.5B | $4.6B | 1.2% | 3.66 | $9.1B | $2.8B | $6.3B | $3B | $3.4B |
| FY2023 · to Dec 31 | $357.8B | 39.3% | $13.7B | $8.3B | 2.3% | 6.47 | $13.4B | $3B | $10.4B | $2B | $3.1B |
| FY2022 · to Dec 31 | $322.5B | 38.9% | $8B | $4.3B | 1.3% | 3.26 | $16.2B | $2.7B | $13.4B | $3.5B | $2.9B |
| FY2021 · to Dec 31 | $292.1B | 39.8% | $13.3B | $8B | 2.7% | 6.02 | $18.3B | $2.5B | $15.7B | $0 | $2.6B |
| FY2020 · to Dec 31 | $268.7B | 39.0% | $13.9B | $7.2B | 2.7% | 5.46 | $15.9B | $2.4B | $13.4B | $0 | $2.6B |
Every number comes from CVS HEALTH Corp's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.